Respiratorius AB (XSAT:RESP) Interest Expense: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:RESP Respiratorius AB XSAT:RESP
33 GF Score
Price kr3.00
View Full Analysis

What is Respiratorius AB Interest Expense?

Respiratorius AB XSAT:RESP -7.69% 33 Interest Expense is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:RESP with a GF Score™ of 33/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Respiratorius AB's interest expense for the three months ended in Mar. 2026 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Respiratorius AB's Operating Income for the three months ended in Mar. 2026 was kr -1.73 Mil. Respiratorius AB's Interest Expense for the three months ended in Mar. 2026 was kr 0.00 Mil. Respiratorius AB has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Respiratorius AB  (XSAT:RESP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Respiratorius AB's Interest Expense for the three months ended in Mar. 2026 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was kr-1.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was kr0.00 Mil.

Respiratorius AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Respiratorius AB had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Respiratorius AB has enough cash to cover all of its debt. Its financial situation is stable.

Respiratorius AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Respiratorius AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Respiratorius AB Interest Expense Chart

Respiratorius AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 0.00 -0.00 -0.05 0.00

Respiratorius AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Apr22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:RESP
33GF Score
Respiratorius AB XSAT:RESP
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Respiratorius AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of kr0.00 Mil mean?
Respiratorius AB (XSAT:RESP) has a Interest Expense of kr0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Respiratorius AB and its competitors.
Is Respiratorius AB's Interest Expense too high?
Respiratorius AB's current Interest Expense is kr0.00 Mil. Overall, Respiratorius AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Respiratorius AB's Interest Expense compare to VRTX and REGN?
Respiratorius AB's Interest Expense of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Respiratorius AB and its competitors. Respiratorius AB's current Interest Expense is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Respiratorius AB stock overvalued right now?
Respiratorius AB (XSAT:RESP) has a current Interest Expense of kr0.00 Mil. The current Interest Expense is kr0.00 Mil. Respiratorius AB's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Respiratorius AB (XSAT:RESP), the current Interest Expense is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Respiratorius AB Business Description

Address Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Respiratorius AB develops pharmaceutical drugs to treat the common diseases namely Cancer, Chronic Obstructive Pulmonary Disease (COPD), and asthma as well as better methods for diagnosing cardiovascular diseases. The company's drug candidates includes RCD405, VAL001, RESP2000, RESP3000, RESP9000, and RESP1000.
33GF Score

Get the complete analysis for XSAT:RESP

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.00
Price